Cushing's disease (CD) is a rare disorder caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma. Chronic exposure to hypercortisolism leads to significant morbidities, which may be only partially reversible after remission of the disease, as well as to impairment of the health-related quality of life (HRQoL) and an increase in mortality. Transsphenoidal surgery (TSS) is the treatment of choice, and recurrence rates vary widely, confirming the need for lifelong follow-up. This review summarises the studies performed on HRQoL, recurrence rates and morbidities in patients who have CD.
Materials and Methods
The available literature was evaluated to address questions on HRQoL, recurrence and morbidities in CD. The literature search was conducted in two stages: (1) identification, review and inclusion of all the most relevant articles published in PubMed having the keywords CD, remission, cure, HRQoL and morbidities and (2) additional hand research conducted on the basis of bibliographies of identified articles, with articles referring to paediatric population and case reports excluded and with papers referring to Cushing's syndrome (CS) reviewed and included only if presenting data on CD.
Quality of Life
HRQoL was initially assessed in CD patients using such generic measures as the Short Form (SF)-36 6 and the SF-12 7 and measures of specific symptoms associated with the disease, including the Hospital Anxiety and Depression Scale (HADS). 8 More recently, two disease-specific measures, the CushingQoL 9 and the Tuebingen CD-25 10, 11 have been developed. Tables 1 and 2 present studies evaluating QoL using various questionnaires in CD patients having active disease or in remission.
Quality of life is significantly impaired not only in patients with active CD, 9 but also in those in long-term remission, 12, 13 regardless of the presence of hormonal deficiencies 9 or treatment strategies, 14, 15 and patients who have CS report more negative illness perceptions than do patients who have other acute or chronic conditions. 16 
Quality of Life Assessed by Generic Questionnaires
Lindholm et al. reported that patients in remission for more than 5 years after initial surgery scored significantly worse in all subscales of SF-36 except for mental health and bodily pain. 17 Compared with healthy controls, CD group showed significantly lower scores in SF-36. No differences in depression (BDI) were found.
When evaluated according to remission rate, the mean BDI showed significantly higher levels of depression and SF-36 scores were lower in the active CD patients than in both the cured CD patients and the controls Patients with CD displayed significantly higher scores in anxiety, depression and psychotic symptoms, with a generalised compromised QoL Active CD was associated with worse scores, but the presence of hypopituitarism or prior pituitary radiotherapy did not determine differences in the scores. 9 Similarly, Santos et al. found that active CD patients scored worse on the CushingQoL questionnaire than did cured subjects. 20 Wagenmakers et al. found that CD patients in remission without hormonal deficiencies scored significantly better than those having hormone deficiencies but significantly worse than the control group on 50 % of the items of the questionnaires. 14 The Tuebingen CD-25 also demonstrated significant differences in all subscales and the total score between active CD patients and healthy controls. 
Recurrence
Transsphenoidal surgery is the treatment of choice in CD, with immediate post-operative remission rates ranging from 59 % to 94 % and recurrence rates from 3 % to 46 %, both depending upon the definition criteria, the duration of follow-up, the number of patients studied and the inclusion of macroadenomas (see Table 3 ). response to desmopressin testing, 30 identification of tumour at surgery and an adenoma histology positive for ACTH. 
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CRH = corticotropin-releasing hormone; GCR = glucocorticoid replacement; LDDST = low-dose dexamethasone suppression test; RM = remission; UBN = 24-hour urinary-free cortisol (UFC) below normal range; UN = 24-hour UFC within normal range; UON = 24-hour UFC over normal range. Recurrence (RC) rates apply to the total number of patients included in each series.
Out of concern about recurrence of CD after initial remission, several al. 34 during a median follow-up of 40 months in patients with a postoperative serum cortisol of <50 nmol/l; similar results were reported after a median follow-up of 58 months by McCance et al. 35 In contrast to these findings, several series have reported recurrence rates of 11.5 % and 15 % despite a serum cortisol <50 nmol/l post surgery. 27, 28 Another possible parameter is the length of adrenal insufficiency post-TSS. Thus it has been suggested that patients who have a shorter duration of adrenal insufficiency have a significantly higher risk of relapse. 36 Accordingly, after successful treatment of CD, there is no accurate criterion that can ensure lifelong cure, and although the evidence shows a more optimal outcome in patients who achieve severe cortisol deficiency after TSS, lifelong follow-up is mandatory.
Morbidities
CD is associated with significant comorbidities -metabolic and vascular complications, osteoporosis, neuropsychiatric dysfunction and immunosuppression -that increase mortality and affect daily life. A number of these may persist long after cure or may even be permanent. factor-α and interleukin-6, C-reactive protein and low ghrelin levels. 40 Moreover, they are characterised by a prothrombotic phenotype attributed to various abnormalities of coagulation and fibrinolysis: these include shortened activated partial thromboplastin time, 43 increased factor VIII, von Willebrand factor, fibrinogen and plasminogen activator inhibitor-1, 43 decreased fibrinolytic capacity 44 and increased α2-antiplasmin. that 27 % of patients having CD in remission for 5 years had persistently atherosclerotic plaques, compared with only 3 % of gender-, age-and body mass index-matched controls. 45 Faggiano et al. also found persistence of the metabolic syndrome, vascular damage and atherosclerotic plaques after disease remission. 46 Thus it is likely that disease remission does not entirely reverse cardiovascular morbidities affecting long-term survival and that lifelong follow-up is needed, with particular emphasis on cardiovascular risk factors.
Bone
Bone loss is attributed to decreased osteoblastic activity, increased osteoclastic bone resorption and impaired enteral calcium absorption. In the ERCUSYN study, osteopenia at the spine and hip was reported in 40 % and 46 % of patients who had CD, respectively, and osteoporosis at the spine and hip in 22 % and 12 %, respectively. 47, 48 Bone mineral density (BMD) does not completely recover following remission, 49, 50 though normalisation in some skeletal sites has been reported in the long-term. 
Immune System
Hypercortisolism induces reversible immunosuppression. During hypercortisolaemia, autoimmune disorders improve but may worsen during remission and new ones develop. 52 There is a high risk of superficial fungal, opportunistic or bacterial infections.
Neuropsychiatric Manifestations
Glucocorticoids are known to influence many functions of the central nervous system. Hypercortisolaemia is associated with depression, disrupted sleep and a wide range of cognitive impairments (derangement of memory -especially short-term -irritability and decreased concentration). High anxiety levels and low externalising behaviour are common emotional disorders. 53 Smaller hippocampal volumes and generalised brain atrophy have been described. The new data on persistent changes in the central nervous system after cure of CD support the hypothesis that psychiatric symptoms and cognitive impairment could be related to structural changes, providing the basis for future research on the neurobiological background of psychological dysfunction in this complex condition.
Conclusions
CD is associated with significant adverse sequelae affecting longterm morbidity, mortality and quality of life. To some extent, the
